Emerging Immunotherapy Approaches for Solid Tumors in 2025

Immunotherapy continues to reshape oncology, yet solid tumors present distinct barriers that hematologic malignancies have largely overcome. In 2025, the field focuses on improving penetration, durability, and patient selection—moving beyond checkpoint inhibitors alone. This analysis reviews current trends, foundational challenges, stakeholder concerns, expected near-term effects, and developments to track.

Recent Trends in Solid Tumor Immunotherapy

Multiple strategies are gaining traction in clinical testing and early adoption:

• Bispecific T‑cell engagers (BiTEs) designed for tumor‑associated antigens (e.g., DLL3, PSMA, HER2) are being evaluated across several solid‑tumor types, with new formats that improve half‑life and reduce infusion‑related reactions.
• CAR‑T cell therapy is expanding into solid tumors via armored constructs that resist exhaustion and target stromal antigens, often combined with novel conditioning regimens.
• Oncolytic viruses (e.g., modified adenoviruses, HSV‑based vectors) are being tested as intratumoral or intravenous agents to prime the tumor microenvironment and boost checkpoint inhibitor efficacy.
• Cancer vaccines using neoantigen prediction platforms and mRNA or peptide‑based formats are moving into larger, randomized trials, particularly for microsatellite‑stable colorectal and pancreatic cancers.
• Immunomodulatory agents targeting the STING pathway, TLRs, or local cytokine delivery aim to convert "cold" tumors into inflamed ones.

Background: Why Solid Tumors Remain Challenging

Unlike liquid tumors, solid tumors feature dense stroma, heterogeneous antigen expression, and an immunosuppressive microenvironment (e.g., T‑regs, myeloid‑derived suppressor cells, hypoxia). Checkpoint inhibitors alone yield durable responses in only a subset of patients—typically those with high tumor mutational burden or mismatch repair deficiency. For the majority, combination regimens and novel modalities are necessary to overcome resistance. The heterogeneity of solid tumors also means that a single approach rarely fits all histologies.

Key Concerns for Patients and Clinicians

• Toxicity profiles: Newer modalities (e.g., bispecific antibodies, oncolytic viruses) can cause cytokine release syndrome, immune effector cell‑associated neurotoxicity, or off‑tumor effects. Managing these while maintaining efficacy is a priority.
• Access and cost: Advanced cell therapies and personalized vaccines remain expensive and logistically demanding; coverage policies and manufacturing scalability are ongoing issues.
• Biomarker uncertainty: Reliable predictive markers for many emerging approaches (e.g., who will benefit from a STING agonist or a particular vaccine signature) are still under investigation.
• Patient selection: Identifying candidates likely to derive benefit without severe toxicity requires better immune profiling—not just PDL‑1 expression or TMB.

Likely Impact on Treatment Landscapes

If current clinical trials confirm early signals, immunotherapy combinations may become standard second‑ or third‑line options for several hard‑to‑treat solid tumors, including pancreatic, hepatocellular, and glioblastoma. The impact will be gradual rather than revolutionary: response rates are expected to improve incrementally, with a fraction of patients achieving durable remissions. Pairing personalized vaccines with checkpoint inhibitors in the adjuvant setting could reduce recurrence rates in high‑risk cancers. However, widespread practice change will depend on confirmatory data from phase 3 studies expected to read out through mid‑2025 and beyond.

• Bispecific antibodies may offer off‑the‑shelf alternatives to CAR‑T for selected antigens, with better tissue penetration.
• Oncolytic virus combinations could increase the fraction of patients who convert from ICI‑nonresponse to response.
• Neoantigen vaccines may shift early‑stage management by prolonging disease‑free survival in patients with minimal residual disease.

What to Watch Next

• Regulatory decisions for first‑in‑class bispecific agents targeting solid‑tumor antigens—FDA and EMA rulings are expected in late 2025.
• Interim readouts from randomized trials combining oncolytic viruses with anti‑PD‑1/PD‑L1 in melanoma and lung cancer.
• Real‑world evidence from expanded access programs for CAR‑T products licensed for solid tumors, particularly regarding manufacturing success rates and durability.
• Emerging biomarker assays (e.g., circulating tumor DNA‑based immune monitoring, single‑cell transcriptomics) that could refine patient stratification for all immunotherapy approaches.
• Cost‑effectiveness analyses and payer coverage decisions for personalized cancer vaccines and multivalent T‑cell engagers.